Page 6 Harnessing data mining for predictive modeling in ocular melanoma cancer care Dagmar Schneider, nandatec research GmbH, Germany Data mining, a crucial element of Personalized Medicine, improves pattern recognition by analyzing extensive datasets, identifying genetic markers, and assessing treatment responses. Uveal melanoma, the predominant eye malignancy, presents significant treatment challenges. Early diagnosis, detection of gene mutations (GNA11, GNAQ), tumor dimensions and individual pathophysiological factors play a crucial role for patient outcome.The rarity, coupled with high mortality and metastasis rates of uveal melanoma, poses obstacles for clinical studies for personalized and targeted therapies. Here we present the combination of predictive modeling and a microfluidic human cell-based eye model for drug development.(3,4) Next-generation sequencing and imaging techniques are used to obtain the genetic and clinical data for predictive modeling. This cost-efficient eye model reveals new targeted treatment pathways and optimizes interventions for patients with uveal melanoma. Furthermore, the combination of artificial intelligence with a human cell based eye model enables long-term research, transforming how we approach the complexity of this challenging malignancy. 1. Shain,A.H., Bagger, M.M.,Yu, R. et al.The genetic evolution of metastatic uveal melanoma. Nat Genet 51, 1123–1130 (2019). 2. Riechardt AI, Kilic E, Joussen AM.The Genetics of Uveal Melanoma: Overview and Clinical Relevance. Klin Monbl Augenheilkd. 2021 Jul;238(7):773-780. 3. Schneider D., Lange T., Jamrozik M.: Microfluidic artificial eye with AI for COVID-19 testing; NIBS- Nanotech for Life Science;Technical Digest; p.19, 05.08.2021. 4. Schneider D., Lange T., Jamrozik M.: 3 D-printed artificial eye with artificial intelligence for allergy testing; Berlin-Brandenburger Optik Tag, excellence in photonics,WFBB, online conference; 31.08.2020. Dagmar Schneider studied Human Medicine at Philipps-University of Marburg and University Hamburg and Biochemistry/Molecular Biology at the Christian-Albrechts-University of Kiel, Germany. She is educated in Biostatistics, clinical epidemiology and clinical trials by Harvard Medical School. D. Schneider has a strong background in Bioinformatics, basic research and led cross-functional teams at the Fraunhofer EMB, Lübeck, as Head of the Cell Technology Laboratory. Her experience, innovative ideas and deep understanding of complex issues in different research areas led to her work as Scientific Business Manager at the Technology Transfer platform Tandem/Medisert, Center of Excellence for Technology and Engineering in Medicine and the BioMedTech Campus in Lübeck. In 2013 Schneider founded nandatec GmbH, a Nanobiotechnology research SME located in Lübeck and Innovation Center Itzehoe, where she functions as Managing Director until today. In 2015 nandatec received the KfW-award Gründerchampions Schleswig-Holstein 2015. She was nominated for the Publikumspreis KfW-Award and Startup of the Year Award at the Micronano conference,Amsterdam in 2016. 2017 Schneiderwas one of three finalists of the IB.SH entrepreneurship award. During her career she was involved in fundraising for projects of over 28 million €. D. Schneider was a member of the selection committee Gründungsstipendium Kiel. Until today she is member of the extended Board of Life Science Nord e.V. and Supervisory Board of LSN Management GmbH. In order to strengthen the technology transfer D. Schneider has memberships in the Signal Transduction Society, the German Society for Stem Cell Research, and functions as Ambassador for nandatec at Biopeople Denmark.
RkJQdWJsaXNoZXIy NDMyMTY=